Ensysce Biosciences, Inc. (ENSC)
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical firm dedicated to developing novel prescription drugs for the treatment of severe pain in the United States, with a specific focus on preventing opioid addiction, misuse, abuse, and overdose. The company leverages two primary technological frameworks: the Trypsin Activated Abuse Protection (TAAP) platform, which creates opioid prodrugs designed to resist abuse, and the Multi-Pill Abuse Resistance (MPAR) platform, engineered to offer protection against overdose through its advanced opioid prodrug technology. Ensysce's pipeline features several key candidates, including PF614, an oxycodone prodrug developed using the TAAP platform, currently undergoing Phase II clinical trials for both acute and chronic pain management. Another product, PF614-MPAR, is a combination of PF614 and nafamostat, in Phase I clinical development to provide overdose protection against excessive oral consumption. Furthermore, the company is exploring an oral and inhaled formulation of nafamostat for potential use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. The company's development efforts also include PF329, an extended-release hydromorphone prodrug similar to PF614. In the area of ADHD treatment, Ensysce is advancing PF8001 and PF8026, which are extended-release and immediate-release amphetamine prodrugs, respectively, aimed at deterring medication abuse. Additionally, PF26810, an extended-release methadone prodrug, is in development for opioid use disorder. Ensysce Biosciences, Inc. operates from its headquarters in La Jolla, California.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Ensysce Biosciences, Inc.
Nasdaq bars a compliance period at 1:250
- 1:15Reverse splitDec 6, 202415 shares → 1
- 1:12Reverse splitMar 31, 202312 shares → 1
- 1:20Reverse splitOct 28, 202220 shares → 1
- 1:1,000Reverse splitJul 27, 20061,000 shares → 1
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $1.76M | $0 | $0 |
| YoY Growth | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $3.4M | $1.56M | $0 |
| Gross Profit | $0 | $0 | $0 | $0 | $0 | $0 | -$1.64M | -$1.56M | $0 |
| Gross Margin | - | - | - | - | - | - | -92.9% | - | - |
| Research and Development | $10.38M | $7.22M | $7.59M | $19.84M | $4.69M | $4.39M | $3.4M | $0 | $0 |
| Selling, General, and Administrative | $4.93M | $4.72M | $5.36M | $6.91M | $18.71M | $1.15M | $6.93M | $0 | $147K |
| Other | -$5.07M | -$5.21M | -$2.23M | -$2.52M | -$3.53M | $0 | -$3.4M | $0 | $0 |
| Total Operating Expenses | $10.24M | $6.73M | $10.72M | $24.22M | $19.87M | $1.61M | $6.93M | -$600K | $147K |
| Operating Income (EBIT) | -$10.24M | -$6.73M | -$10.72M | -$24.22M | -$19.87M | -$1.61M | -$8.57M | -$959K | -$147K |
| Operating Margin | - | - | - | - | - | - | -485.7% | - | - |
| Interest Expense | $19K | $1.29M | $354K | $110K | $1.29M | $995K | $0 | $0 | $0 |
| Interest Income | $0 | $0 | $0 | $1.25M | $3.21M | $720K | $4.25M | $3.63M | $0 |
| Other Income (Expense) | $65K | -$1.26M | $92K | $14K | -$9.28M | $2.45M | -$1.53M | $3.63M | $119K |
| Income Before Tax (EBT) | -$10.18M | -$7.99M | -$10.63M | -$24.21M | -$29.15M | -$161K | -$10.1M | $2.68M | -$28K |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $554K | $4K |
| Net Income | -$10.18M | -$7.99M | -$10.61M | -$24.17M | -$29.08M | $57K | -$10.1M | -$1.34M | -$31K |
| Net Income Margin | - | - | - | - | - | - | -572.7% | - | - |
| Supplementary Data | |||||||||
| EPS | -3.98 | -4.57 | -4.69 | -139.44 | -355.68 | 0.56 | -1.66 | -0.22 | -0.01 |
| Diluted EPS | -3.98 | -4.57 | -4.69 | -139.44 | -355.68 | 0.56 | -1.66 | -0.22 | -0.01 |
| Weighted Average OS | 2.56M | 1.75M | 2.26M | 179,932 | 84,018 | 4.46M | 6.09M | 6.01M | 5.98M |
| EBITDA | -$10.15M | -$6.7M | -$10.27M | -$24.1M | -$27.85M | -$1.61M | -$8.57M | $2.68M | -$28K |
| EBITDA Margin | - | - | - | - | - | - | -485.7% | - | - |
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
| Assets | |||||||||
| Current Assets | |||||||||
| Cash and Cash Equivalents | $4.31M | $3.5M | $1.12M | $3.15M | $12.26M | $194K | $342K | $1.66M | $2.09M |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $4.31M | $3.5M | $1.12M | $3.15M | $12.26M | $194K | $342K | $1.66M | $2.09M |
| Accounts Receivable | $420K | $124K | $98K | $277K | $442K | $0 | $174K | $171K | $0 |
| Inventory | $0 | $0 | $0 | $0 | -$442K | $0 | $0 | $0 | $0 |
| Other Current Assets | $18K | $18K | $18K | $1.33M | $2.59M | $24K | $69K | $0 | $0 |
| Total Current Assets | $7.24M | $5.34M | $2.29M | $5.3M | $15.66M | $348K | $619K | $1.92M | $2.31M |
| Long-Term Assets | |||||||||
| Property, Plant & Equipment Net | $124K | $0 | $0 | $0 | $24.72B | $151 | $351 | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $202.92M | $200.12M |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $86K | $253K | $419K | $586K | -$24.72M | $4K | $5K | $0 | $0 |
| Total Long-Term Assets | $210K | $253K | $419K | $586K | $755K | $4K | $5K | $202.92M | $200.12M |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $7.45M | $5.6M | $2.71M | $5.89M | $16.42M | $352K | $624K | $204.83M | $202.43M |
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts Payable | $3.27M | $1.36M | $1.94M | $2.94M | $301K | $1.72M | $541K | $0 | $0 |
| Short-Term Debt | $307K | $302K | $855K | $4.27M | $12.75M | $4.25M | $2.62M | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $4K |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $159K | $0 | $0 | $0 |
| Other Current Liabilities | $0 | $0 | $0 | $0 | $0 | $670K | $2.93M | $438K | $153K |
| Total Current Liabilities | $4.57M | $2.21M | $3.33M | $9.46M | $16.48M | $7.01M | $7.3M | $438K | $156K |
| Long-Term Liabilities | |||||||||
| Long-Term Debt | $0 | $0 | $0 | $140K | $4.44M | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $6.75M | $0 | $7M | $7M |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $2K | $0 |
| Other Long-Term Liabilities | $0 | $10K | $26K | $310K | $3.65M | $0 | $0 | $0 | $0 |
| Total Long-Term Liabilities | $0 | $10K | $26K | $450K | $8.09M | $6.75M | $0 | $7M | $7M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | -$6.75M | $0 | $0 | $0 |
| Total Liabilities | $4.57M | $2.22M | $3.36M | $9.91M | $24.58M | $7.01M | $7.3M | $7.44M | $7.16M |
| Stockholders' Equity | |||||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $192.39M | $190.27M |
| Common Stock | $459 | $136 | $315 | $53 | $124 | $2K | $6K | $604 | $673 |
| Retained Earnings | -$139.72M | -$129.54M | -$121.56M | -$110.93M | -$85.85M | -$55.96M | -$56.02M | $2.09M | -$31K |
| Comprehensive Income & Other | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$604 | -$673 |
| Other Stockholders' Equity | $142.93M | $133.25M | $121.23M | $107.22M | $77.97M | $49.52M | $49.33M | $195.3M | $195.3M |
| Total Equity | $3.21M | $3.71M | -$323K | -$3.71M | -$7.88M | -$6.44M | -$6.68M | $197.39M | $195.27M |
| Minority Interest | -$329K | -$328K | -$328K | -$315K | -$280K | -$218K | $0 | $0 | $0 |
| Total Liabilities and Equity | $7.78M | $5.93M | $3.04M | $6.2M | $16.7M | $569K | $624K | $204.83M | $202.43M |
| Supplementary Data | |||||||||
| Total Debt | $307K | $302K | $855K | $4.43M | $17.21M | $4.27M | $2.62M | $0 | $0 |
| Net Debt | -$4M | -$3.2M | -$269K | $1.29M | $4.95M | $4.08M | $2.28M | -$1.66M | -$2.09M |
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
| Operating Activities | |||||||||
| Net Income | -$10.18M | -$7.99M | -$10.63M | -$24.21M | -$29.15M | -$161K | $366K | -$1.34M | -$31K |
| Depreciation & Amortization | $7K | $0 | $0 | $0 | $151 | $201 | $201 | $0 | $0 |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | -$2.45M | -$2K | $2K | $0 |
| Stock-Based Compensation | $177K | $111K | $879K | $1.07M | $122K | $179K | $0 | $0 | $0 |
| Changes in Working Capital: | |||||||||
| Accounts Receivable | -$296K | -$27K | $179K | $165K | -$442K | $174K | $0 | -$171K | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | -$174K | $0 | $0 | $0 |
| Accounts Payable | $1.82M | -$579K | -$1.23M | $2.64M | -$1.42M | $1.18M | $0 | $317K | $112K |
| Other Working Capital | -$4K | -$246K | $108K | $2.67M | $562K | -$999K | $2.46M | $126K | -$213K |
| Total Working Capital Change | $1.52M | -$851K | -$947K | $5.48M | -$1.3M | $185K | $2.46M | $273K | -$102K |
| Other Non-Cash Items | $671K | $1.22M | -$86K | -$233K | $22.09M | $997K | $8.17M | -$317K | -$231K |
| Net Cash from Operating | -$7.81M | -$7.5M | -$10.78M | -$17.89M | -$8.24M | -$1.25M | $10.99M | -$1.24M | -$252K |
| Investing Activities | |||||||||
| Capital Expenditures | -$124K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Acquisitions | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Purchases of Investments | $0 | $0 | $0 | $0 | $0 | $0 | -$566K | $0 | -$200M |
| Sales of Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Investing Activities | $0 | $0 | $0 | $5K | $0 | $183.4M | $0 | $839K | $0 |
| Net Cash from Investing | -$124K | $0 | $0 | $5K | $0 | $183.4M | -$566K | $839K | -$200M |
| Financing Activities | |||||||||
| Debt Repaid | - | $485K | -$605K | -$6.13M | -$13.91M | -$1.1M | -$566K | - | - |
| Common Stock Issuance | $5.87M | $12.21M | $9.05M | $3.78M | $6.63M | $0 | -$9K | -$32K | $202.34M |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 | -$11.58M | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | -$1.11M | -$1.84M | -$900K | -$1.14M | -$226K | $0 | $0 | $0 | $0 |
| Net Cash from Financing | $8.74M | $9.88M | $8.76M | $8.77M | $20.31M | $1.1M | -$11.03M | -$32K | $202.34M |
| Forex Effect | $0 | $0 | $0 | $0 | $0 | -$183.4M | $0 | $0 | $0 |
| Net Change in Cash | $808K | $2.38M | -$2.02M | -$9.12M | $12.07M | -$147K | -$597K | -$432K | $2.09M |
| Supplementary Data | |||||||||
| Operating Cash Flow | -$7.81M | -$7.5M | -$10.78M | -$17.89M | -$8.24M | -$1.25M | $10.99M | -$1.24M | -$252K |
| Capital Expenditure | -$124K | $0 | $0 | $0 | $0 | $0 | $4 | $0 | $0 |
| Free Cash Flow | -$7.93M | -$7.5M | -$10.78M | -$17.89M | -$8.24M | -$1.25M | $10.99M | -$1.24M | -$252K |
| Cash at Beginning | $3.5M | $1.12M | $3.15M | $12.26M | $194K | $342K | $1.66M | $2.09M | $0 |
| Cash at End | $4.31M | $3.5M | $1.12M | $3.15M | $12.26M | $194K | $1.06M | $1.66M | $2.09M |